Recursion Pharmaceuticals announced positive Phase 2 data for REC-4881 showing significant polyp reductions in FAP patients, and encouraging Phase 1 results for REC-1245 in cancer treatment. Sanofi has optioned a new immunology candidate from Recursion, expected to enter Phase 1 trials in 2027. The company extended its cash runway into 2029 following a successful funding round and appointed Fred Hassan as Board Chair. These developments highlight Recursion's progress in AI-driven drug discovery and clinical advancement, with plans for further trials and partnerships.
Recursion Pharmaceuticals shares are currently priced at USD 3.81 on Pluang, down 5.46% in the last day. The stock has a market cap of $2.43 billion and a 52-week trading range between $2.84 and $5.52. These figures are as of Nov 03, 2026 04:43 WIB.
Recursion Pharmaceuticals announced positive Phase 2 results for REC-4881, an oral MEK1/2 inhibitor, in treating familial adenomatous polyposis (FAP). The TUPELO trial showed a 47% median reduction in total polyp burden after 12 weeks of treatment, w...
Recursion Pharmaceuticals appointed Fred Hassan as Chair of its Board, effective October 31, 2026. Hassan brings over 40 years of pharmaceutical experience, including leadership roles at Schering-Plough and BridgeBio Pharma, known for driving drug ap...
